{"title":"OUD患病率和成本研究","authors":"Alison Knopf","doi":"10.1002/adaw.34537","DOIUrl":null,"url":null,"abstract":"<p>Last month Avalere Health released a report totaling the costs of opioid use disorder (OUD) and the impact of treatment in limiting those costs. The study, supported by Indivior, found that the average case of OUD costs $695,000 a year, most of which goes to the criminal justice system. Treatment, however, lowers those costs. The study focuses on the benefits of long-acting injectable buprenorphine, made by Indivior, which was found to be more cost-effective than sublingual buprenorphine or methadone.</p>","PeriodicalId":100073,"journal":{"name":"Alcoholism & Drug Abuse Weekly","volume":"37 22","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Study of prevalence and costs of OUD\",\"authors\":\"Alison Knopf\",\"doi\":\"10.1002/adaw.34537\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Last month Avalere Health released a report totaling the costs of opioid use disorder (OUD) and the impact of treatment in limiting those costs. The study, supported by Indivior, found that the average case of OUD costs $695,000 a year, most of which goes to the criminal justice system. Treatment, however, lowers those costs. The study focuses on the benefits of long-acting injectable buprenorphine, made by Indivior, which was found to be more cost-effective than sublingual buprenorphine or methadone.</p>\",\"PeriodicalId\":100073,\"journal\":{\"name\":\"Alcoholism & Drug Abuse Weekly\",\"volume\":\"37 22\",\"pages\":\"1-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alcoholism & Drug Abuse Weekly\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/adaw.34537\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alcoholism & Drug Abuse Weekly","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/adaw.34537","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Last month Avalere Health released a report totaling the costs of opioid use disorder (OUD) and the impact of treatment in limiting those costs. The study, supported by Indivior, found that the average case of OUD costs $695,000 a year, most of which goes to the criminal justice system. Treatment, however, lowers those costs. The study focuses on the benefits of long-acting injectable buprenorphine, made by Indivior, which was found to be more cost-effective than sublingual buprenorphine or methadone.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
